Bibliography
- Vyas VK, Ghate M. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev Med Chem 2011;11(12):1039-55
- Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem 2013;56(8):3148-67
- Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93(3):198-208
- Maroun J, Ruckdeschel J, Natale R, et al. Multicenter phase II study of brequinar sodium in patients with advanced lung cancer. Cancer Chemother Pharmacol 1993;32(1):64-6
- Kobayashi K, Nakashima A, Nagata H, et al. Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis. Inflamm Res 2001;50(1):24-31
- Chen J, Xia J, Axelsson B, et al. An N-(alkylcarbonyl)anthranilic acid derivative prolongs cardiac allograft survival synergistically with cyclosporine A in a high-responder rat model. Transpl Immunol 2010;23(4):180-4
- Herrlinger KR, Diculescu M, Fellermann K, et al. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 2013;7(8):636-43
- 4SC AG, 4SC Announces topline results of phase IIb trial of vidofludimus in rheumatoid arthritis. 2011. Available from: http://www.dgap.de/link.php?template=4sc&anzahl=10&sprache=en&bis=20111231&von=20110101&typ=corporate&id=676628
- Almirall SA. Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors. WO2008077639; 2008
- Almirall SA. Sodium salt of 5-cyclopropyl-2-{[2-(2,6- difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor. WO2010102824; 2010
- Almirall SA. 2-[(3,5-Difluoro-3′-methoxy-1,1′-biphenyl-4-yl)amino]nicotinic Acid For The Treatment Of Psoriasis. WO2013076170; 2013
- Godessart N, Andres M, Auli M, et al. Pharmacological profile of LAS186323, a novel non-hepatotoxic DHODH inhibitor for the oral treatment of multiple sclerosis and other autoimmune disorders. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010
- Erra M, Moreno I, Sanahuja J, et al. Biaryl analogues of teriflunomide as potent DHODH inhibitors. Bioorg Med Chem Lett 2011;21(24):7268-72
- ASLAN Pharmaceutical. ASLAN announces a global license agreement with Almirall for LAS186323 in rheumatoid arthritis. 2012. Available from: http://www.aslanpharma.com/download/Press%20Release%20-%20Almirall-ASLAN%20Licensing.pdf
- Almirall SA. Process for manufacturing 2-[(3,5-difluoro-3′-methoxy-1,1′-biphenyl-4-yl)amino]nicotinic acid. WO2011045059A1; 2011
- Risek B, Pozzi A, Gilula NB. Modulation of gap junction expression during transient hyperplasia of rat epidermis. J Cell Science 1998;111(pt 10):1395-404
- Boyd AS. Leflunomide in dermatology. J Am Acad Dermatol 2012;66(4):673-9
- Jones PBB, White DHN. Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol Res Rev 2010;2:53-71